Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
US8212045B2 · kind B2 · utility
2Cited by
28References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 15, 2008 |
| Grant date | Jul 3, 2012 |
| Priority date | — |
| Expiry date | Sep 15, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.